Search the Newsreel

FDA milestones and Beam ruling frame outlook for Prime Medicine (NASDAQ: PRME)

Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M

Generate Biomedicines (GENB) posts Q2 loss but holds $457.4M cash after IPO

Janus Henderson Group PLC Purchases 8,623 Shares of Cintas Corporation $CTAS

Janus Henderson Group PLC increased its stake in Cintas Corporation (NASDAQ:CTAS) by 20% in the first quarter, acquiring an additional 8,623 shares, bringing their total holdings to 51,716 shares valued at $8.75 million. Cintas has consistently exceeded quarterly expectations, reporting strong revenue growth and …

Pacer Advisors Inc. Lowers Stake in Cintas Corporation $CTAS

Pacer Advisors Inc. significantly reduced its stake in Cintas Corporation (NASDAQ:CTAS) by 34.8% in the first quarter, selling over 21,000 shares. Despite this, Cintas continues to exceed earnings expectations, reporting $1.29 EPS and $2.91 billion in revenue, and has increased its quarterly dividend. The …

Q2 2026 Praxis Precision Medicines Inc Earnings Call Transcript

Praxis Precision Medicines Inc. held its Q2 2026 earnings call, discussing positive FDA feedback for ulixacaltamide and relutrigine, and strong financial positioning with $1.4 billion in cash. The company also addressed the setback in its vormatrigine program and reported increased operating expenses and cash …

Generate Biomedicines (Nasdaq:GENB) - Stock Analysis

Generate Biomedicines (GENB) is utilizing machine learning for drug discovery and development, holding a market cap of US$1.8 billion. While revenue is projected to grow significantly, the company is currently unprofitable and faces risks such as declining earnings forecasts and a cash runway of …

Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD

Quantinno Capital Management LP significantly increased its stake in Revolution Medicines (RVMD) by 97.6% in the first quarter, now owning 63,360 shares valued at $6.16 million. Despite the company reporting a wider-than-expected quarterly loss of $3.06 per share, institutional investors hold 94.34% of the …

Dimensional Fund Advisors LP Raises Holdings in Disc Medicine, Inc. $IRON

Dimensional Fund Advisors LP significantly increased its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 76.4% in the first quarter, now holding 394,447 shares valued at $25.2 million. Despite insider selling totaling $7.6 million, institutional investors collectively own 83.7% of the company. Analysts maintain a …

Curious about National CineMedia (NCMI) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Prime Medicine (PRME) Earnings Date and Reports 2026

Praxis Precision Medicines (PRAX) Earnings Date and Reports 2026

Cineverse sets Aug. 13 call to discuss quarterly results

A Closer Look at Vicinity Centres’ (ASX:VCX) Latest Market Move and Property Position

Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results

Cinemark Holdings (CNK) Is Up 8.6% After Record Spider-Man Weekend And Q2 Results - Has The Bull Case Changed?

Cinemark Holdings (CNK) saw an 8.6% increase after a record-breaking "Spider-Man: Brand New Day" weekend and strong Q2 2026 results, with revenue reaching US$1,086.4 million and net income US$139.4 million. While these results bolster the short-term bull case, they also highlight the company's reliance …

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock drop. Investors who purchased Disc Medicine securities may be entitled to compensation and …

Press Release: Editas Medicine Announces Second Quarter 2026 Results and Business Updates

Editas Medicine (NASDAQ: EDIT) announced its second quarter 2026 financial results and provided business updates. The company highlighted recent progress in its CRISPR-based therapeutic programs and discussed its financial position, offering insights into its strategic direction and upcoming milestones for the remainder of the …

CX Institutional Acquires 31,548 Shares of Cincinnati Financial Corporation $CINF

CX Institutional significantly increased its stake in Cincinnati Financial Corporation (NASDAQ:CINF) by 1,405.9% in the second quarter, purchasing an additional 31,548 shares. This brings their total holdings to 33,792 shares, valued at approximately $6.26 million. Despite missing the consensus earnings estimate for the quarter, …

Earnings call transcript: Revolution Medicines lifts spending outlook in Q2 2026

Revolution Medicines ended Q2 2026 with $3.9 billion in cash and investments and increased its 2026 spending forecast to $2.1 billion to $2.2 billion to advance late-stage oncology programs and prepare for a potential first product launch. The company's lead drug, daraxonrasib, cleared a …

Editas Medicine (NASDAQ:EDIT) Issues Earnings Results

Editas Medicine (NASDAQ:EDIT) announced its quarterly earnings, reporting an adjusted loss of $0.15 per share, surpassing the consensus estimate of a $0.27 loss, with revenue of $11.89 million, significantly exceeding analyst expectations of $2.85 million. Despite beating revenue and EPS estimates, the company remains …

Revolution Medicines Q2 Net Loss Widens

Revolution Medicines reported a significant widening of its net loss in Q2, increasing to $111.4 million from $70.8 million year-over-year, largely due to increased research and development expenses. Despite the loss, the company exceeded revenue expectations with $9.3 million, up from $2.1 million in …

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine (EDIT) reported a Q2 loss of $0.15 per share, surpassing the Zacks Consensus Estimate of a $0.3 loss and representing a 50% surprise. The company also beat revenue estimates with $11.89 million, significantly higher than the $3.58 million from the previous year. …

Revolution Medicines falls on second quarter earnings miss

Revolution Medicines (NASDAQ:RVMD) reported a significant earnings miss for the second quarter, with a loss of -$3.06 per share against an estimated -$1.96. The net loss for the quarter reached $644.4 million, impacted by a non-cash charge related to an acquisition. Despite the financial …

Cintas Corp. stock underperforms Wednesday when compared to competitors

Cintas Corp. (CTAS) shares fell by 1.10% on Wednesday, closing at $201.40, marking its fifth consecutive day of losses. This underperformance occurred on a mixed trading day, with the Dow Jones Industrial Average rising and the S&P 500 Index declining. The stock's performance was …

Star Sports Medicine Sets Board Meeting to Approve Interim Results and Consider Dividend

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Revolution Medicines announced its Q2 2026 financial results and provided an update on corporate progress, highlighting the FDA's acceptance of daraxonrasib's New Drug Application for metastatic pancreatic cancer and the rapid implementation of an Expanded Access Program. The company also reported encouraging new combination …

Editas Medicine (EDIT) CFO tax-related share sale executed under preset plan

Editas Medicine's CFO, Amy Parison, sold 678 shares of common stock at $2.58 per share on August 3, 2026. This transaction was executed under a pre-established Rule 10b5-1 plan to cover tax withholding obligations from restricted stock units that vested on August 1, 2026, …

Editas Medicine (Nasdaq: EDIT) equity deal lifts cash to $211.6M

Editas Medicine reported a Q2 2026 net loss of $18.2 million, significantly trimmed from $53.2 million a year prior, and saw collaboration revenues increase to $11.9 million. The company's cash, cash equivalents, and marketable securities totaled $211.6 million as of June 30, 2026, boosted …

Cintas Announces Executive Leadership Restructuring

Cintas, a Counselor Top 40 distributor, has restructured its executive leadership by separating the roles of CEO and President. Todd Schneider will remain CEO, while Jim Rozakis, a 27-year veteran of the company, has been promoted to President and COO. This move is intended …

Praxis Precision earnings on deck as commercialization nears

Praxis Precision Medicines Inc. is set to report second-quarter results, with investors focused on cash burn and commercial readiness as the company awaits two key FDA drug approval decisions. Analysts have a strong buy rating with significant upside potential. The company's cash runway and …

Hiroshima Bank selects nCino for lending overhaul

Hiroshima Bank has chosen nCino's AI banking platform to modernize its consumer lending operations, including mortgage loans. This initiative is part of the bank's Mid-Term Management Plan 2024, aiming to improve sales processes and operational efficiency. The integration of nCino will move the entire …

Cinemark (CNK) Upgraded to Strong Buy: Here's What You Should Know

Investors might want to bet on Cinemark Holdings (CNK), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock …

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

Generate Biomedicines (NASDAQ: GENB) is one of the top five largest holdings of Nvidia (NASDAQ: NVDA), run by CEO Jensen Huang. Let that sink in for a moment. The largest publicly traded company by market capitalization has roughly $10.4 million invested in a clinical-stage …

Cincinnati Financial (CINF) Beat On Earnings, Is The Stock Fully Priced?

nCino (NCNO) insider Jeanette Sellers files Form 144 to sell 1,536 shares

nCino, Inc. insider Jeanette E. Sellers has filed a Form 144 to sell 1,536 shares of common stock, valued at $29,998.08, through Fidelity Brokerage Services on NASDAQ. These shares are part of restricted stock that vested on August 1, 2026, received as compensation. The …